npt-15392 has been researched along with Neoplasms* in 6 studies
1 review(s) available for npt-15392 and Neoplasms
Article | Year |
---|---|
Immunopharmacology of the hypoxanthine containing compounds isoprinosine and NPT 15392.
Topics: Animals; Antibody-Producing Cells; Autoimmune Diseases; Humans; Hypoxanthines; Immunity; In Vitro Techniques; Infections; Inosine; Inosine Pranobex; Leukocytes; Lymphocyte Activation; Mice; Neoplasms; T-Lymphocytes | 1984 |
5 other study(ies) available for npt-15392 and Neoplasms
Article | Year |
---|---|
Chemically defined immunotherapeutic agents.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Aziridines; Benzimidazoles; Cimetidine; Ditiocarb; Humans; Hypoxanthines; Inosine Pranobex; Leucine; Levamisole; Mice; Neoplasms; Pyran Copolymer; Tuftsin | 1983 |
The immunopharmacology of synthetic immunomodulators.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Aziridines; Ditiocarb; Glucans; Humans; Hypoxanthines; Immunity; Inosine Pranobex; Interferon Inducers; Leucine; Levamisole; Lynestrenol; Neoplasms | 1983 |
Isoprinosine and NPT 15392: immunomodulation and cancer.
These data demonstrate that both Isoprinosine and NPT 15392 are active nontoxic biological response modifiers that qualify for studies in cancer patients. Because of their immunomodulating properties, these agents are expected to be most appropriate in the treatment of immunosuppressed patients who are prone to infection or recurrence following cytoreductive therapy. Topics: Adjuvants, Immunologic; Animals; Humans; Hypoxanthines; Immunity; Inosine; Inosine Pranobex; Lymphocytes; Neoplasms; Rats; Species Specificity | 1983 |
Immunomodulation by NPT 15392 in cancer patients under chemotherapy.
A clinical trial of NPT 15392, a purine derivative, was run in ten head and neck cancer patients presenting signs of immunosuppression and undergoing repeated chemotherapy. A battery of ten tests was used to assess the immune status of the subjects. Those tests included skin tests, lymphocyte investigations (count, E-rosetting, membrane fluorescence and lymphoblastic transformation) and determination of serum levels of C'3 fraction of complement and IgA. The drug induced transitory, immune stimulation during or after treatment without any side effects. NPT 15392 seemed to selectively exert an action on T lymphocytes. Inasmuch as transitory, immune stimulation and secondary immune depression were noted after treatment, the therapeutic protocol for use of this drug should be reexamined. Topics: Adjuvants, Immunologic; Adult; Female; Humans; Hypoxanthines; Lymphocytes; Male; Middle Aged; Neoplasms; Phytohemagglutinins | 1983 |
New immunostimulating drug.
Topics: Adjuvants, Immunologic; Animals; Humans; Hypoxanthines; Immunity; Mice; Neoplasms | 1980 |